AXSM / Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss

Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quar more_horizontal

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? more_horizontal

Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over tim more_horizontal

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates. more_horizontal

Axsome Therapeutics (AXSM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to los more_horizontal

Axsome Therapeutics' novel treatments for central nervous system disorders gain traction, with promising revenues from drugs Auvelity and Sunosi. Desp more_horizontal

The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate abo more_horizontal

Axsome Therapeutics' current drugs and pipeline programs look especially promising. Brookfield Renewable could double in six years if it hits the low more_horizontal